During the last session, KalVista Pharmaceuticals Inc (NASDAQ:KALV)’s traded shares were 0.5 million, with the beta value of the company hitting 0.08. At the end of the trading day, the stock’s price was $12.00, reflecting an intraday gain of 2.17% or $0.26. The 52-week high for the KALV share is $15.50, that puts it down -29.17 from that peak though still a striking 39.17% gain since the share price plummeted to a 52-week low of $7.30. The company’s market capitalization is $596.59M, and the average intraday trading volume over the past 10 days was 0.77 million shares, and the average trade volume was 552.96K shares over the past three months.
KalVista Pharmaceuticals Inc (KALV) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. KALV has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.83.
KalVista Pharmaceuticals Inc (NASDAQ:KALV) trade information
KalVista Pharmaceuticals Inc (KALV) registered a 2.17% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 2.17% in intraday trading to $12.00, hitting a weekly high. The stock’s 5-day price performance is 13.85%, and it has moved by -0.83% in 30 days. Based on these gigs, the overall price performance for the year is 1.01%. The short interest in KalVista Pharmaceuticals Inc (NASDAQ:KALV) is 5.86 million shares and it means that shorts have 9.43 day(s) to cover.
The consensus price target of analysts on Wall Street is $28, which implies an increase of 57.14% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $28 and $28 respectively. As a result, KALV is trading at a discount of -133.33% off the target high and -133.33% off the low.
Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 2M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -20.06%. While earnings are projected to return -3.28% in 2025, the next five years will return 20.85% per annum.
KALV Dividends
KalVista Pharmaceuticals Inc is due to release its next quarterly earnings on 2025-Mar-11. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
KalVista Pharmaceuticals Inc (NASDAQ:KALV)’s Major holders
KalVista Pharmaceuticals Inc insiders own 1.36% of total outstanding shares while institutional holders control 113.55%, with the float percentage being 115.11%. VR ADVISER, LLC is the largest shareholder of the company, while 174.0 institutions own stock in it. As of 2024-06-30, the company held over 6.25 million shares (or 13.5179% of all shares), a total value of $73.62 million in shares.
The next largest institutional holding, with 4.22 million shares, is of TANG CAPITAL MANAGEMENT LLC’s that is approximately 9.1252% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $49.7 million.
Also, the Mutual Funds coming in first place with the largest holdings of KalVista Pharmaceuticals Inc (KALV) shares are SMALLCAP WORLD FUND INC and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . Data provided on Dec 31, 2024 indicates that SMALLCAP WORLD FUND INC owns about 3.37 shares. This amounts to just over 6.79 percent of the company’s overall shares, with a $40.49 million market value. The same data shows that the other fund manager holds slightly less at 1.4, or about 2.81% of the stock, which is worth about $16.78 million.
